Abstract
We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Protein & Peptide Letters
Title:Amylin Conjugation with Methoxyl Polyethyleneglycol
Volume: 20 Issue: 11
Author(s): Mariana F. A. N. Guterres, Luiz Henrique Guerreiro, Bruno Melo-Ferreira, Luiza C. S. Erthal and Luís Maurício T. R. Lima
Affiliation:
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Abstract: We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Export Options
About this article
Cite this article as:
F. A. N. Guterres Mariana, Guerreiro Henrique Luiz, Melo-Ferreira Bruno, S. Erthal C. Luiza and T. R. Lima Maurício Luís, Amylin Conjugation with Methoxyl Polyethyleneglycol, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990067
DOI https://dx.doi.org/10.2174/09298665113209990067 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research <i>In silico</i> Studies on the Interaction Between Bioactive Ligands and DPPIV: Insights on Potential Candidates for the Treatment of type 2 Diabetes Mellitus
Medicinal Chemistry Virtual Screening Based Discovery of PTP1B Inhibitors and Their Biological Evaluations
Letters in Drug Design & Discovery Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Electron Spin Resonance as a Powerful Tool for Studying Antioxidants and Radicals
Current Medicinal Chemistry Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy CD26 Inhibition Enhances Perfusion Recovery in ApoE-/-Mice
Current Vascular Pharmacology Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Insulin Neuritis and Diabetic Cachectic Neuropathy: A Review
Current Diabetes Reviews Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Glucose Lowering Activity of the Aqueous Extract of Warionia saharae in Normal and Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders
Current Aging Science Endocrine Orchestration of Cardiovascular, Gastrointestinal and Hypothalamic Control
Current Medicinal Chemistry Platelet Resistance to Antiplatelet Drugs
Recent Patents on Cardiovascular Drug Discovery Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research